ESMO 2024
Did you miss us at the ESMO Congress 2024?
If so, you can click the “Contact Us” button at the top of this page. Our team members will be pleased to talk to you.
Did you attend our Satellite Symposium: A new comprehensive approach to lung cancer treatment?
If not, you are in luck, the webcast of the BeiGene-sponsored Satellite Symposium is available in the Congress Resources section of our website.
This symposium, co-chaired by Prof. Silvia Novello and Prof. Tony Mok, provided an overview of tislelizumab data in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Audience participation was encouraged, with panel discussions and audience Q&A throughout the session. Dr. Mariano Provencio presented data from the pivotal trial in resectable NSCLC (neo-adjuvant/adjuvant). Prof. Mok and Prof. Martin Reck debated whether single agent immuno-oncology (IO) is the only treatment option for NSCLC with high programmed death-ligand 1 (PD-L1) expression, or whether combination regimens are a suitable alternative. Prof. Luis Paz-Ares discussed treatment options in NSCLC with low PD-L1 expression. Finally, Prof. Novello presented data from the pivotal trial in first-line (1L) SCLC. Following the presentations, there was a general panel discussion and an opportunity for the audience to ask the faculty questions.
